Dyne Therapeutics (DYN) announced that the Ministry of Health, Labour and Welfare in Japan has granted Orphan Drug designation for zeleciment basivarsen or z-basivarsen, for the treatment of myotonic muscular dystrophy type 1. Z-basivarsen is currently being evaluated in the Phase 1/2 ACHIEVE clinical trial.
Z-basivarsen has also been granted Breakthrough Therapy, Fast Track and Orphan Drug designations from the FDA, and Orphan Drug designation from the European Medicines Agency for the treatment of individuals with muscular dystrophy type 1.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.